Loading...
XBRUSEQUA
Market cap35mUSD
Dec 20, Last price  
0.76EUR
1D
9.46%
1Q
-17.14%
IPO
-89.76%
Name

Sequana Medical NV

Chart & Performance

D1W1MN
XBRU:SEQUA chart
P/E
—
P/S
47.67
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
14.41%
Rev. gr., 5y
-7.10%
Revenues
712k
-22.82%
1,684,9181,488,7991,303,9751,029,171970,636963,280370,500922,687712,173
Net income
-33m
L+5.85%
000-13,983,224-14,977,446-19,106,205-23,615,080-30,763,084-32,563,574
CFO
-29m
L+5.75%
000-9,875,346-18,482,352-17,005,228-23,617,366-27,481,845-29,063,346
Earnings
May 23, 2025

Profile

Sequana Medical NV, a commercial stage medical device company, engages in the development of platform for the treatment of fluid overload in liver disease, malignant ascites, and heart failure. The company's products include alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; Direct Sodium Removal (DSR) for the treatment of persistent congestion due to heart failure; and alfapump DSR, a fully implanted system for direct sodium removal therapy in patients with fluid overload due to heart failure. It operates in Belgium, Germany, France, Switzerland, and internationally. The company was founded in 2006 and is headquartered in Ghent, Belgium.
URL
https://www.sequanamedical.com/
IPO date
Feb 11, 2019
Employees
70
Domiciled in
BE
Incorporated in
BE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
712
-22.82%
923
149.04%
370
-61.54%
Cost of revenue
12,947
16,839
13,394
Unusual Expense (Income)
NOPBT
(12,235)
(15,916)
(13,024)
NOPBT Margin
Operating Taxes
466
387
393
Tax Rate
NOPAT
(12,701)
(16,303)
(13,417)
Net income
(32,564)
5.85%
(30,763)
30.27%
(23,615)
23.60%
Dividends
Dividend yield
Proceeds from repurchase of equity
15,786
28,420
22,771
BB yield
-14.74%
-20.80%
-16.54%
Debt
Debt current
8,087
4,790
283
Long-term debt
10,166
13,719
8,562
Deferred revenue
Other long-term liabilities
668
228
510
Net debt
15,568
(452)
(837)
Cash flow
Cash from operating activities
(29,063)
(27,482)
(23,617)
CAPEX
(711)
(677)
(326)
Cash from investing activities
(721)
(653)
(338)
Cash from financing activities
13,461
37,324
22,435
FCF
(7,867)
(17,102)
(13,981)
Balance
Cash
2,584
18,875
9,600
Long term investments
100
86
82
Excess cash
2,649
18,915
9,664
Stockholders' equity
(205,110)
(170,998)
(140,770)
Invested Capital
203,832
186,665
148,578
ROIC
ROCE
957.66%
EV
Common stock shares outstanding
26,774
22,770
18,213
Price
4.00
-33.33%
6.00
-20.63%
7.56
-35.93%
Market cap
107,096
-21.61%
136,617
-0.78%
137,690
-23.78%
EV
122,665
137,645
139,302
EBITDA
(11,574)
(15,605)
(12,615)
EV/EBITDA
Interest
4,288
880
573
Interest/NOPBT